Novel polyurethane-based nanoparticles of infliximab to reduce inflammation in an in-vitro intestinal epithelial barrier model.
Anti-Inflammatory Agents
/ administration & dosage
Caco-2 Cells
Cell Survival
/ drug effects
Drug Carriers
/ administration & dosage
Humans
Infliximab
/ administration & dosage
Interleukin-8
/ immunology
Intestinal Mucosa
/ metabolism
Lipopolysaccharides
Monocytes
/ drug effects
Nanoparticles
/ administration & dosage
Polyurethanes
/ administration & dosage
Tumor Necrosis Factor-alpha
/ immunology
Caco-2
Cellular uptake
IBD
Inflammation
Infliximab
Nanoparticles
TNF-α
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
30 Jun 2019
30 Jun 2019
Historique:
received:
21
11
2018
revised:
01
05
2019
accepted:
10
05
2019
pubmed:
16
5
2019
medline:
18
12
2019
entrez:
16
5
2019
Statut:
ppublish
Résumé
In this study we examined the potential of novel biodegradable polymers of polyesterurethane (PU), and its PEGylated (PU-PEG) form as nanocarriers of Infliximab (INF), to treat inflammation in an in-vitro epithelial model. Nanoparticles (NPs) formulated were of average size of 200-287 nm. INF loading of NPs (INF-NPs) resulted in an increase in size and zeta potential. No cytotoxicity was observed for any of the NPs. Cellular interaction and uptake of PU NPs were similar compared with polycaprolactone (PCL) NPs and significantly higher to Poly(lactic-co-glycolic) acid (PLGA) NPs. Cellular interaction was higher for corresponding PEG-NPs. INF-PU and INF-PU-PEG NPs showed a rapid rate and extent of recovery of the epithelial barrier function in inflamed Caco-2 cell monolayers and decreased cytokine levels in inflamed monocytes. Results obtained in this study are promising and the potential of PU and PU-PEG NPs for drug delivery and targeting to treat gastrointestinal inflammation warrants further investigation.
Identifiants
pubmed: 31085256
pii: S0378-5173(19)30378-3
doi: 10.1016/j.ijpharm.2019.05.025
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
CXCL8 protein, human
0
Drug Carriers
0
Interleukin-8
0
Lipopolysaccharides
0
Polyurethanes
0
TNF protein, human
0
Tumor Necrosis Factor-alpha
0
Infliximab
B72HH48FLU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
533-542Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.